3 results
Approved WMOCompleted
Primary objective: The primary objective is to assess the efficacy and safety of nemolizumab (CD14152) after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
Approved WMORecruiting
To assess which treatment leads to the best patient outcome on the short term (1 year) and the long term (5 years)
Approved WMORecruiting
The primary objective is to assess the long-term safety of nemolizumab (CD14152) in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD).The secondary objective is to assess the long-term efficacy of nemolizumab (CD14152) in…